@article{84eb78d68e66495ebdeb799bc2292097,
title = "Reply to Karthaus",
author = "Patterson, {Thomas F.} and Walsh, {Thomas J.}",
note = "Funding Information: guidelines state that posaconazole can be recommended for the subgroup of hematopoietic stem cell transplant recipients with graft-versus-host disease who are at high risk of invasive aspergillosis and for neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome who are at high risk of invasive aspergillosis [1]. This recommendation is supported by 2 randomized clinical trials involving those populations [2, 3]. As described in the text of the guidelines, the recommendation for prophylaxis is predicated on the fact that a heterogeneity of risks of invasive aspergillosis exists in those populations of patients [4–8]. In patients with a lower incidence of infection, the risk-to-benefit ratio for prophylaxis is reduced. As Karthaus notes in his letter to the editor in this issue of Clinical Infectious Diseases [9], the increased risks associated with posaconazole can be clinically significant, including the 3 cardiac events— decreased ejection fraction, prolongation of the QT or QTc interval, and torsades de pointes—that were each reported in single patients (1 patient with each event) receiving posaconazole in the study by Cornely et al. [2, 9].",
year = "2008",
month = aug,
day = "1",
doi = "10.1086/589924",
language = "English (US)",
volume = "47",
pages = "427--428",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",
}